Stock futures dipped on Thursday as investors weighed President Trump’s 90-day tariff reprieve for select countries, which notably excluded China. The U.S. raised tariffs on Chinese goods to 125% on Wednesday, with Trump citing a “lack of respect” following Beijing’s retaliatory actions, intensifying trade war fears. Meanwhile, a cooler-than-expected CPI reading for March offered some relief on the inflation front.

Here are some of Thursday's biggest stock movers:

Biggest stock gainers

• DexCom (DXCM) +5% – Shares gained after the company announced FDA clearance for its Dexcom G7 15 Day continuous glucose monitoring system for adults with diabetes. The device, offering up to 15.5 days of use, is now the longest-lasting CGM system on the market and boasts a leading accuracy with a MARD of 8.0%. DexCom plans to launch the G7 15 Day in the U.S. during the second half of 2025.
• Trump Media (NASDAQ:DJT) +7% – Shares extended gains Thursday morning after a double-digit surge Wednesday, when the stock jumped as much as 22.4%, ranking among the top gainers in the communications services sector. The rally followed a Truth Social post by Donald Trump stating, “THIS IS A GREAT TIME TO BUY!!! DJT,” just hours before he announced a 90-day pause on the reciprocal tariffs he unveiled earlier this month. Volume topped 14.45M shares, more than twice its 3-month average. Short interest stands at 5.47%. Year to date, DJT is down 49%, compared to a 7% drop in the S&P 500 (SP500).

Biggest stock losers

• Constellation Brands (NYSE:STZ) -4% – Shares slipped despite a Q4 beat, as the company’s FY2026 outlook disappointed investors amid trade policy uncertainty. FY26 EPS guidance of $12.60–$12.90 came in well below the $13.94 consensus, while organic net sales are expected to range from -2% to +1%. The company also cut its FY27–FY28 sales growth forecast to flat to +3% (from +1% to +3%). Constellation targets FY26 operating cash flow of $2.7–$2.8B and free cash flow of $1.5–$1.6B. It also plans to divest its mainstream wine brands to The Wine Group and will review its organizational structure, aiming for over $200M in annualized cost savings by FY28.
• U.S. Steel (NYSE:X) -11% – Shares plunged after President Donald Trump reiterated his opposition to the company's acquisition by Japan’s Nippon Steel, despite previously suggesting openness to a minority stake. “We love Japan, but U.S. Steel is a special company,” he stated. The stock had earlier surged to a 52-week intraday high of $46.18 following Trump’s call for a national security review of the deal, but momentum reversed sharply on renewed takeover concerns.
• Easterly Government Properties (DEA) -6% – Shares declined after the company announced a 32% cut to its quarterly dividend, lowering it to $0.18 per share from $0.265. The board also approved a 1-for-2.5 reverse stock split, set to take effect on April 28, 2025, under which shareholders will receive one share for every 2.5 held. Post-split, the dividend will adjust to $0.45 per share. CEO Darrell Crate noted the changes aim to align payout ratios with cash flow and free up capital to support the firm's expanding development pipeline.
• CarMax (KMX) -18% – Shares tumbled after the used car retailer’s Q4 profit surged 81% Y/Y but still missed Street expectations. EPS came in at $0.58 vs. $0.66 consensus, despite solid performance driven by higher unit sales, gross profit, and CAF income. Revenue rose 6.7% Y/Y to $6B, slightly topping estimates. However, profit per vehicle slipped 3.8% to $1,045, which weighed on sentiment. For FY2026, CarMax plans to open six new locations and four reconditioning/auction centers, with capital expenditures projected at $575M.
• Novavax (NASDAQ:NVAX) -24% – Shares plummeted after U.S. Health Secretary Robert F. Kennedy Jr. raised concerns over the effectiveness of the company’s COVID-19 vaccine, pointing to its single-antigen design as a limitation for combating respiratory illnesses. His comments come amid delays in the vaccine’s full U.S. approval following the resignation of the FDA's top vaccine official, Dr. Peter Marks. Currently, the shot remains authorized only under emergency use. RFK Jr. noted that future focus will likely shift toward multi-antigen vaccines, which the NIH is already developing.